Related Experiment Video
Updated: Aug 16, 2026

Light/dark Transition Test for Mice
Published on: November 13, 2006
NS-7 (Nippon Shinyaku)
1National Research Council of Canada, Receptors and Ion Channels Group, Institute for Biological Sciences, Building M-54, Montreal Road, Ottawa, ON K1A 0R6, Canada. Dan.Small@nrc.ca
Abstract:
Nippon Shinyaku is developing NS-7, a sodium and calcium channel blocker, as a neuroprotectant for use following cerebral infarction [249336]. It entered phase I trials for the treatment of acute stage cerebrovascular disorders in 1997 [271963]. As of November 1999, Nippon Shinyaku was preparing to start phase II studies in Japan [347972]. In November 1999, Nippon Shinyaku granted Schering exclusive developing and marketing rights to NS-7. Schering will conduct clinical trials in Europe and the US [347972].
Related Concept Videos
Nociception
The Synapse
The Seven Crystal Systems: Overview
Amnesia
The severity and duration of memory loss vary depending on the type and underlying cause. Amnesia is classified into two main types: retrograde and anterograde.
Retrograde amnesia is marked by the loss of memories formed before the onset of the condition. Patients may recall distant past events but often forget those occurring shortly before the incident.
Anterograde...
What is a Nervous System?
The Sympathetic Nervous System
